Figure 1. LSD1 Inhibitor Treatment of Epidermal Progenitors Unleashes a Pro-differentiation Transcriptional Program.

(A–C) Differentially expressed genes after 2 days of LSD1 inhibition by GSK-LSD1 (A and B) and 2-PCPA (C).

(D) Overlap between genes upregulated by 2-day GSK-LSD1 (863 genes) and 2-PCPA (1,161 genes).

(E) GO analysis of genes upregulated by 2-day GSK-LSD1 (863 genes).

(F and G) Log2 fold change values of the 50 most highly upregulated (F) and all 37 significantly downregulated (G) transcription factor-encoding genes after 2-day GSK-LSD1.

(H) Overlap between genes significantly upregulated by 2-day GSK-LSD1 (863 genes) and during in vitro epidermal differentiation (902 genes).

(I) Overlap between transcription factor-encoding genes significantly upregulated by 2-day GSK-LSD1 (93 genes) and during in vitro epidermal progenitor differentiation (103 genes).

(J) Overlap of genes significantly upregulated by 6-day GSK-LSD1 (1,678 genes) and during in vitro epidermal progenitor differentiation (902 genes).

(K) Overlap between transcription factor-encoding genes significantly upregulated by 6-day GSK-LSD1 (332 genes) and during in vitro epidermal progenitor differentiation (103 genes).

(L) transcription factor-encoding genes commonly upregulated by 2-day GSK-LSD1 and in vitro epidermal progenitor differentiation, sorted by decreasing log2 fold change between GSK-LSD1- and DMSO-treated samples.

(M) The 25 most differentially regulated transcription factor-encoding genes commonly upregulated by 6-day GSK-LSD1 and in vitro epidermal progenitor differentiation, sorted by decreasing log2 fold change between GSK-LSD1- and DMSO-treated samples.

(N) Increased expression of human genes that define the gene ontology term ‘‘keratinocyte differentiation’’ (GO:0030216) upon in vitro epidermal progenitor differentiation, after 2- or 6-day GSK-LSD1.